AIA GROUP LIMITED · 友邦保险

Recommendation history

• —BuyBuy: AIA delivered a broad-based H1 recovery, with Group VONB up 37%, EV equity at US$70.6bn, operating ROEV at 13.3% and free surplus of US$16.3bn; the interim dividend rose 5% and US$5.5bn has been returned through buybacks. The main tension is whether Hong Kong’s Mainland visitor-led surge and Mainland China’s reopening rebound remain durable, as no explicit forward earnings guidance was provided.
• —HoldAIA delivered a strong 2021: VONB rose 18% to more than US$3.3bn, OPAT increased 6% to US$6.4bn, VONB margin expanded to 59.3%, and the group approved a US$10bn buyback alongside an 8% dividend increase. Its high-quality agency franchise, Asian exposure and 399% solvency cover support the bull case, but Mainland China execution, regulatory change and the lack of explicit 2022 growth guidance argue for a hold rather than a clean buy.
• —No clear callConstructive, but not an automatic buy without valuation support: AIA delivered broad-based operating strength, with VONB up 10% to a record $3.2bn, OPAT per share up 13%, operating ROE at a record 17.5%, and UFSG per share up 10%. The bull case is a high-margin, agency-led compounding model with CSM up 10% underlying and a 10% interim-dividend increase; the tension is that some support came from favorable variances, while China’s ambitious growth target and AI benefits remain largely unquantified.
• —BuyBuy: AIA delivered a strong, broad-based first half, with VONB up 21% to US$959 million, or 25% at constant exchange rates, IFRS operating profit up 12% to US$1.6 billion, free-surplus generation of US$2.1 billion and a 17% interim-dividend increase. China VONB rose 58%, Hong Kong 29% and bancassurance 61% on constant exchange rates, supporting the agency-led growth thesis; the main tension is that the call provided no formal forward guidance and offered limited evidence on valuation or competitive threats.
• —BuyAIA delivered another high-quality compounding year: VONB rose 22% to nearly US$4.0bn, OPAT increased 13% to US$5.3bn, operating ROE reached 14.5%, and the dividend rose 14% to HK$1.14 per share plus a HK$0.095 special dividend. China VONB grew 30%, agency VONB 26%, and the 60% VONB margin improved four percentage points, supporting a buy stance; the main tensions are market volatility, pending CBA regulatory approval, and limited quantified forward guidance.
• —HoldHold: AIA delivered resilient first-half fundamentals, with VONB above US$1.5 billion, OPAT up 4% to US$3.2 billion, free surplus rising US$3.6 billion to US$20.6 billion, and a 6% interim-dividend increase. The diversified Asian distribution platform and improving June/July sales support the recovery case, but management provided no quantified forward growth outlook and the new Amplify Health strategy remains unproven amid China, market, and execution risks.
• —BuyBuy: AIA delivered a strong H1 with VONB up 25% to US$2.5bn, OPAT and UFSG up 10% per share, ROEV at 16.5% and ROE at 15.3%. The new 2023–26 OPAT-per-share CAGR target of 9–11% and 75% net-free-surplus payout policy materially improve visibility and shareholder returns, though China macro risk and the use of a per-share target—which benefits from buy-backs—temper the upside case.